ADC Therapeutics, a Swiss cancer drug developer, has postponed its U.S. IPO, citing adverse conditions, reported Reuters. The firm was planning on raising $200 million for the IPO. ADC’s backers include Auven Therapeutics and AstraZeneca.
Nearly there!
We have just sent you an email so you can verify your account. Please check your spam or junk folder just in case it's been delivered there.
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please email: customerservices@peimedia.com.-
Sign in or Register
-
Issues with signing in? Click here
Not yet registered? Register now
Become a subscriber, Subscribe now
-
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.
